Lifecore Biomedical, Inc.
LFCR
$4.36
-$0.01-0.12%
NASDAQ
| 09/30/2025 | 05/25/2025 | 02/23/2025 | 11/24/2024 | 08/25/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.31% | 0.47% | 7.23% | 16.47% | 23.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.31% | 0.47% | 7.23% | 16.47% | 23.42% |
| Cost of Revenue | 10.29% | 2.50% | -2.74% | 2.26% | 5.80% |
| Gross Profit | -4.06% | -3.71% | 34.71% | 57.30% | 79.95% |
| SG&A Expenses | -11.16% | 7.18% | 15.25% | 13.38% | 12.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.35% | 3.47% | 2.44% | 5.35% | 7.27% |
| Operating Income | 47.50% | -67.80% | 35.16% | 59.26% | 66.45% |
| Income Before Tax | -655.06% | -506.58% | -122.29% | 67.81% | 108.29% |
| Income Tax Expenses | 472.86% | -76.50% | -110.00% | -44.89% | -82.14% |
| Earnings from Continuing Operations | -668.89% | -515.02% | -116.99% | 67.65% | 108.14% |
| Earnings from Discontinued Operations | -- | -- | -99.24% | 103.32% | 102.83% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -596.99% | -422.35% | -121.20% | 80.29% | 106.58% |
| EBIT | 47.50% | -67.80% | 35.16% | 59.26% | 66.45% |
| EBITDA | 2,976.15% | -201.57% | 74.00% | 101.79% | 101.06% |
| EPS Basic | -582.76% | -431.05% | -118.57% | 79.18% | 106.73% |
| Normalized Basic EPS | -238.25% | -252.22% | -556.42% | 82.78% | 139.23% |
| EPS Diluted | -2,219.60% | -676.98% | -75.87% | 76.05% | 101.53% |
| Normalized Diluted EPS | -297.89% | -307.22% | -4,113.74% | 72.28% | 127.41% |
| Average Basic Shares Outstanding | 19.16% | 14.23% | 9.46% | 4.23% | 1.70% |
| Average Diluted Shares Outstanding | 8.45% | 3.93% | -0.45% | 4.16% | 11.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |